Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Nightfood Holdings Inc. (NGTF) Eyes Growth with CarryOut Acquisition

Nightfood Holdings (OTCQB: NGTF) is at it again. The Tarrytown, NY-based company built its name with sleep-friendly snacks and is now starting to stack its portfolio with opportunistic acquisitions. On July 17, Nightfood announced a letter of intent to acquire SWC Group Inc., doing business as Carryoutsupplies.com, or CarryOut for short. This move signals Nightfood’s […]

PaxMedica Inc. (NASDAQ: PXMD) Developing Treatments for Underserved Neurological Disorders

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for suramin to treat Human African Trypanosomiasis, a century-old treatment in East Africa. In April 2024, PaxMedica underscored its commitment to global health by responding to an […]

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces. InMed Pharmaceuticals […]

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have […]

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like ALS (amyotrophic lateral sclerosis) and multiple sclerosis (“MS”). In a recent Emerging Growth Conference 73 – Biotech Feature, Clene presented new findings and information pertinent to current and potential investors. Under the leadership of CEO Rob Etherington, […]

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain […]

D-Wave Quantum Inc. (NYSE: QBTS) Adds Second Annealing Quantum Computer in the U.S. and Unveils New Hybrid Quantum Solver

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, continues to make strides in the development and deployment of quantum computing technology. The company recently announced two major advancements: the introduction of a new hybrid quantum solver and the deployment of a second U.S.-based Advantage quantum computer. D-Wave has revealed plans […]

 

From Our Blog

Why 2026 Is a Pivotal Year for Private, Pre-IPO, and Microcap Investing, and What That Means for DealFlow Discovery

January 23, 2026

As we head into January 2026, the capital markets landscape is in a period of subtle but consequential transition, one that has real implications for the direction of private company financings, pre-public valuations, and the small-cap ecosystem that DealFlow Discovery Conference now reflects. For years, microcap investing sat at the intersection of retail enthusiasm and […]

Rotate your device 90° to view site.